Key facts
- This page summarizes Robert E. Gagnon's Form 4 filing for Opus Genetics, Inc. (IRD).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 08 Sep 2026, 16:05.
Robert E. Gagnon - 03 Sep 2026 Form 4 Insider Report for Opus Genetics, Inc. (IRD)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- IRD
- Reported as of
- 03 Sep 2026
- Net transaction value
- -$127,212
- SEC form
- 4
- Accepted by SEC
- 08 Sep 2026, 16:05:48 UTC
- Prior SEC filing
- 27 Jul 2026
- Next SEC filing
- 30 Sep 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Amy Rabourn, by Power of Attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert E. Gagnon filed Form 4 for Opus Genetics, Inc. (IRD) on 08 Sep 2026.
Change
- Previous filing in this sequence was filed on 27 Jul 2026.
- Current net transaction value: -$127,212.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001504983
Primary reporting owner
Gagnon Robert E.
- Relationship
- Chief Financial Officer
- Address
- C/O OPUS GENETICS, INC., 8 DAVIS DRIVE, SUITE 220, DURHAM
- Signature
- /s/ Amy Rabourn, by Power of Attorney
- Signature date
- 08 Sep 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IRD
transaction
Common Stock
Sale
- Transaction value
- $127,212
- Shares
- -28,000
- Change %
- -4.8%
- Price
- $4.54
- Shares after
- 556,375
- Date
- 03 Sep 2026
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
A portion of the shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Issuer, to satisfy tax withholding obligations that arose in connection with the vesting and settlement of restricted stock units, and the remainder of the shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 30, 2026. The Rule 10b5-1 trading plan is a pre-arranged written trading plan pursuant to which shares of the Issuer's common stock are sold automatically based on a predetermined formula that was established by the Reporting Person at a time when the Reporting Person was not aware of any material nonpublic information about the Issuer.
Footnote F2
The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $4.29 to $4.79, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.